Biomarkers.

Background: Amyloid beta (Aβ) deposition marks an early stage in the progression of Alzheimer's disease (AD), detectable in-vivo years before symptoms emerge and targeted by recently FDA-approved drugs. This has propelled advancements in understanding, measuring, and treating AD, paving the way for disease prevention in those at risk. However, the psychological impact of disclosing Aβ status to cognitively unimpaired individuals remains underexplored.

Developing Topics.

Background: We aim to describe the imaging findings in pre-symptomatic and early-symptomatic individuals carrying a recently described novel APP duplication rearrangement causing early-onset AD (EOAD).

Method: We studied individuals from one pedigree that carry APP duplication and CH 5 mutation gain that had structural and resting state functional (rs-f) brain MRI. Non-carrier family members were assessed as controls.

Gene expression analysis of the response by Escherichia coli to seawater.

Gene expression of Escherichia coli cells exposed to seawater for 20 h was compared to that of exponentially growing cells (mops-glucose 0.2%) using DNA microarray technology. The expression of most (ca.